iKang Revenue and Competitors
Estimated Revenue & Valuation
- iKang's estimated annual revenue is currently $7.9M per year.
- iKang's estimated revenue per employee is $126,000
Employee Data
- iKang has 63 Employees.
- iKang grew their employee count by -2% last year.
iKang Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $14.1M | 101 | 5% | N/A | N/A |
#2 | $1.6M | 19 | -71% | N/A | N/A |
#3 | $212.8M | 1063 | 5% | $65M | N/A |
#4 | $6.8M | 54 | 8% | N/A | N/A |
#5 | $12.9M | 92 | 2% | $23.1M | N/A |
#6 | $1M | 12 | N/A | N/A | N/A |
#7 | $106.5M | 599 | -17% | $2.3M | N/A |
#8 | $35.6M | 231 | 6% | N/A | N/A |
#9 | $38.3M | 249 | 5% | N/A | N/A |
#10 | $45M | 299 | -4% | $102.6M | N/A |
What Is iKang?
A first mover in healthcare management industry, iKang Guobin has become the largest independent healthcare management company in China. iKang Guobin offers products covering physical checkups, primary care service & medical management. It has a nationwide presence in 90 cities through self operated medical centers and partnerships with over 400 of the best hospitals in China. iKang Guobin currently owns 20 medical facilities in 7 cities, and plans to double that number within the next two years. www.ikang.com
keywords:N/A
N/A
Total Funding
63
Number of Employees
$7.9M
Revenue (est)
-2%
Employee Growth %
N/A
Valuation
N/A
Accelerator
iKang News
The police spokesperson in Akwa Ibom, Odiko Macdon, in a statement in Uyo on Thursday, said the suspects were traced to their hideouts at Ikang...
IKang Group; Japanese Red Cross; Rich Healthcare; Mayo Clinic; Nuffield Health; Cleveland Clinic; Cooper Aerobics; Samsung Total Healthcare Center; Milord...
The hard-to-reach community is located 20 minutes away from Ikang community be road. Are you a Man 40 yrs and above?
Other Companies in Beijing
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $4M | 63 | -42% | $4.1B |
#2 | N/A | 64 | 2% | N/A |
#3 | $4.2M | 64 | N/A | N/A |
#4 | $8.6M | 66 | -7% | N/A |
#5 | $15.3M | 67 | 5% | N/A |